COMPANY

Cellsight Technologies, Inc.

HQ: San Francisco, CA source · cellsighttech.com ↗ · West Coast

Location: San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Non-small Cell Lung Cancer Alzheimer Disease Covid19 SARS-CoV Infection Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit Graft Versus Host Disease Advanced Non Small Cell Lung Cancer HIV Infections Squamous Cell Carcinoma of the Head and Neck [18F]F-AraG [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine) [18F]F-Ara-G

11Trials (company is sponsor)7NIH grants

Funding and NIH signals

NIH award NIH awarded $883K (SBIR Phase II 5R44AG094397-02, continuation, notice Aug 25, 2026). NIH RePORTER 5R44AG094397-02 (Aug 25, 2026)
Evidence (1 event)
- Aug 25, 2026 · NIH RePORTER 5R44AG094397-02
  Organization: CELLSIGHT TECHNOLOGIES, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44AG094397-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 882921; Administering IC: National Institute on Aging; Project title: Imaging intracerebral and systemic T cell immunity in patients with Alzheimer's disease using 18F-F-AraG; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 25, 2026 Grant Government grant — SBIR: $882,921 (annual award, as published), announced Aug 25, 2026. Agency: NIH/NIA. Source: government award database. source ↗
May 16, 2026 Trial start Phase 2: [18F]F-AraG PET Imaging in Alzheimer's Disease source ↗
Sep 18, 2025 Grant Government grant — SBIR: $871,261 (annual award, as published), announced Sep 18, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Nov 1, 2023 Trial start Phase 2: Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG source ↗
Oct 31, 2023 Trial start Phase 2: Test-retest Evaluation of [18F]F-AraG PET source ↗
Mar 1, 2022 Trial start Phase 2: A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors source ↗
Apr 15, 2021 Trial start Phase 2: Imaging Immune Activation in COVID-19 source ↗
Apr 15, 2021 Trial start Phase 2: Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer source ↗
Sep 21, 2018 Trial start Phase 2: Imaging Immune Activation in HIV by PET-MR source ↗
May 15, 2018 Trial start Phase 1: Detection of Graft Versus Host Disease With [18F]F-AraG source ↗
May 1, 2017 Trial start Phase 1: [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy source ↗
May 1, 2017 Trial start Phase 1: Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) source ↗
2015-02 Trial start Phase 1: Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans source ↗

Upcoming milestones

Oct 1, 2027 (ESTIMATED) · Phase 2 · Imaging Immune Activation in COVID-19 · NCT04815096
Sep 16, 2029 (ESTIMATED) · Phase 2 · [18F]F-AraG PET Imaging in Alzheimer's Disease · NCT07611357

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Aug 25, 2026 Government grant — SBIR: $882,921 (annual award, as published), announced Aug 25, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Sep 18, 2025 Government grant — SBIR: $871,261 (annual award, as published), announced Sep 18, 2025. Agency: NIH/NIA. Source: government award database. source ↗

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT07611357	[18F]F-AraG PET Imaging in Alzheimer's Disease	Phase 2	Not yet recruiting	May 16, 2026	Sep 16, 2029 (estimated)
NCT04815096	Imaging Immune Activation in COVID-19	Phase 2	Recruiting	Apr 15, 2021	Oct 1, 2027 (estimated)
NCT04260256	A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors	Phase 2	Terminated	Mar 1, 2022	Mar 1, 2026 (actual)
NCT03367962	Detection of Graft Versus Host Disease With [18F]F-AraG	Phase 1	Completed	May 15, 2018	Jun 21, 2023 (actual)
NCT06107374	Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG	Phase 2	Recruiting	Nov 1, 2023	Dec 31, 2025 (estimated)
NCT03684655	Imaging Immune Activation in HIV by PET-MR	Phase 2	Recruiting	Sep 21, 2018	Oct 1, 2025 (estimated)
NCT06084806	Test-retest Evaluation of [18F]F-AraG PET	Phase 2	Recruiting	Oct 31, 2023	Oct 31, 2025 (estimated)
NCT04726215	Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer	Phase 2	Unknown status (ClinicalTrials.gov)	Apr 15, 2021	Oct 15, 2024 (estimated)
NCT03142204	[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy	Phase 1	Unknown status (ClinicalTrials.gov)	May 1, 2017	2024-05 (estimated)
NCT03129061	Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Phase 1	Completed	May 1, 2017	Dec 1, 2022 (actual)
NCT02323893	Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans	Phase 1	Completed	2015-02	Dec 31, 2017 (actual)

NIH awards 7

Annual award amounts. Total $6.4M.

2022 NIH contract (government contract; not a grant and not an investment round) 75N91022C00015-0-9999-1 FY2022: $1,995,174 awarded for that fiscal year; activity N44 (OTHER_NIH); PI LEVI, JELENA; recipient as written: CELLSIGHT TECHNOLOGIES, INC., SAN FRANCISCO, C source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 75N91019C00012-0-9999-1 FY2019: $300,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI LEVI, JELENA; recipient as written: CELLSIGHT TECHNOLOGIES, INC., SAN FRANCISCO, CA. source ↗
Aug 31, 2018 NIH award 5R44CA221624-02 FY2018: $1,020,835 awarded for that fiscal year; activity R44 (SBIR); PI LEVI, JELENA; recipient as written: CELLSIGHT TECHNOLOGIES, INC., SAN FRANCISCO, CA. Monitoring immune response to im source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 261201800024C-0-0-1 FY2018: $299,641 awarded for that fiscal year; activity N01 (OTHER_NIH); PI LEVI, JELENA; recipient as written: CELLSIGHT TECHNOLOGIES, INC., SAN FRANCISCO, CA. SBI source ↗
Sep 21, 2017 NIH award 1R44CA221624-01 FY2017: $1,020,143 awarded for that fiscal year; activity R44 (SBIR); PI LEVI, JELENA; recipient as written: CELLSIGHT TECHNOLOGIES, INC., SAN FRANCISCO, CA. Monitoring immune response to im source ↗
2013 NIH contract (government contract; not a grant and not an investment round) 261201300063C-0-0-1 FY2013: $1,499,971 awarded for that fiscal year; activity N44 (OTHER_NIH); PI YAGHOUBI, SHAHRIAR; recipient as written: CELLSIGHT TECHNOLOGIES, INC., SAN FRANCISCO, source ↗
2011 NIH contract (government contract; not a grant and not an investment round) 261201100119C-0-0-1 FY2011: $247,568 awarded for that fiscal year; activity N43 (OTHER_NIH); PI YAGHOUBI, SHAHRIAR; recipient as written: CELLSIGHT TECHNOLOGIES, INC., SAN FRANCISCO, C source ↗